DDInter1379 DDInter1676
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Palbociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Palbociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Escitalopram
Palbociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Palbociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sufentanil
Palbociclib {u} may lead to a major life threatening interaction when taken with {v} Amprenavir
Palbociclib {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil
Palbociclib may lead to a major life threatening interaction when taken with Amprenavir
Palbociclib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated